Monday, August 25, 2025

9th Circuit finds laches in false advertising case

World Nutrition Inc. v. Advanced Supplementary Tech. Corp., 2025 WL 2427613, No. 24-4976 (9th Cir. Aug. 22, 2025)

Over a partial dissent, the court of appeals reverses the district court’s refusal of a laches defense in this false advertising case, giving no weight to the public’s interest in avoiding deception. (Lower court ruling discussed here.)

The parties both advertised some of their respective enzyme products as having, to varying degrees, enteric coating. After a bench trial, the district court (1) rejected defendant AST’s laches defense; (2) ruled in favor of World Nutrition on its claim and in favor of AST on two of its three counterclaims; and (3) entered a monetary judgment in World Nutrition’s favor because it determined that AST made more than World Nutrition did from the deception.

The district court abused its discretion by rejecting AST’s laches defense. Laches requires unreasonable delay plus prejudice. Reasonability considers both the time allotted by the “analogous” state statute of limitations and any “legitimate excuse” for delay. But the district court considered only prejudice, which can’t be viewed in isolation from the delay. When a court determines that “the most analogous state statute of limitations expired before suit was filed,” a “strong presumption in favor of laches” attaches, and ourts must “bear[ ] in mind th[at] presumption” when evaluating prejudice.

World Nutrition knew—or at least should have known—about its false-advertising claim by 2011, and the analogous statute of limitations is Arizona’s three-year period for fraud. That expired in 2014, five years before World Nutrition sued. Thus, the district court abused its discretion in failing to evaluate prejudice without a presumption thereof.

Given that presumption, AST showed laches. World Nutrition offered no legitimate excuse for its delay. And the district court, addressing a different issue, relied on its determination that “AST centered its advertising—and spent substantial funds—on the claim that its products were more effective because of the enteric coating.” That finding, which was not clearly erroneous, showed prejudice, which exists when a defendant invests resources—whether through advertising or otherwise—to “build a valuable business around [the specific business asset or practice being challenged] during the time that the plaintiff delayed.”

The court of appeals affirmed the district court’s finding  that AST failed to meet its burden to prove the literal falsity of World Nutrition’s advertising of its liquid products as “100%” effective. Still, a good result for AST.

Judge Ryan Nelson dissented in part, because he would have sent it back to the district court to reassess laches in the first instance.


Thursday, August 21, 2025

graphic designer's photos and hashtag using former client's name didn't infringe TM

Hilber v. Malley’s Candies, Inc., 2025 WL 2402329, No. 1:22-CV-02305 (N.D. Ohio Aug. 19, 2025)

Advertising is often created by independent contractors, which has copyright risks when things go sour. Here, the court denies summary judgment on the defendant’s implied license defense, and also rejects its overreaching trademark counterclaims about its designer’s use of images on the designer’s social media accounts.

Malley’s is a chain of candy and confectionary stores in Northeastern Ohio, and Hilber is an independent consulting graphic design artist. Hilber charged Malley’s an hourly rate of $50 per hour to perform the graphic design work for advertising campaigns, with no written agreement. Malley’s purchased a camera for her to use to create photography and artwork for advertising campaigns. Between 2018 and 2021, she invoiced Malley’s for more than $230,000. She provided print-ready files, not the native files, and was the only one to make modifications. The relationship broke down and produced this lawsuit.

Malley’s previous graphic designer independent contractors didn’t think they owned their work for Malley’s. (They were wrong, but that expectation is highly relevant to the implied license.)

The court denied summary judgment on the implied license for continued use/modification. Malley’s also counterclaimed against Hilber’s use of photographs of Malley’s products on her Instagram and Facebook accounts and on her website:

Instagram

Website

Facebook, I think

Hilber allegedly used these photographs of Malley’s artwork, as well as the hashtags “#malleys” and “#graphicdesigner,” to advertise her services as a graphic designer.

The court was unconvinced. Since we’re in the Sixth Circuit, what might be considered nominative fair use elsewhere is just mushed into the general infringement/ “use in a trademark way” inquiry. Malley’s was unable to identify anyone who was actually confused or any profit Hilber made from the uses.

Malley’s appealed to Sixth Circuit caselaw holding that continued unauthorized use of a trademark is enough to establish likelihood of confusion. But those were terminated franchisee cases, where the defendants were providing the same service as the franchisor. “Hilber is not holding herself out as providing the same products as Malley’s. She is sharing Malley’s social media posts and displaying images of work she created.” Given the unrelatedness of the goods or services, confusion was highly unlikely. [Courts default to source confusion when they don’t like extended confusion theories, usually without even explaining why they aren’t addressing sponsorship/affiliation confusion.] “[N]o rational trier of fact could find that Hilber, by displaying Malley’s products and logos on her social media or personal website, likely caused confusion among consumers seeking to purchase Malley’s products.”

Hilber’s use of the hashtags “#malleys” and “#graphicdesign” in Instagram posts was also ok:

 

In the cases Malley’s cites, the defendants used hashtags to create a public impression their products or services were endorsed by the trademark owner. In those case, the use of hashtags was likely to cause confusion because the defendants were selling the same products or services as the trademark owner and wanted to convey an association to obtain business. The cases are distinguishable. Hilber is not selling candy or chocolate. She is a graphic designer. She is not unfairly competing with Malley’s for consumers looking to buy chocolate by using the hashtag “#malleys.” Hilber has not received any

State dilution claims also failed, even though the trademark was “identical.”  Without evidence of “personal gain,” the court wasn’t even willing to accept that Hilber was “using” a junior mark “in commerce,” nor was there evidence of dilution. [How could there be?] “And Malley’s cannot distinguish Hilber’s posts from the thousands of other social media users that post Malley’s marks.”

 

 


literal falsity wasn't enough without evidence of lost sales or harm to goodwill

G. W. Aru, LLC v. W. R. Grace & Co.-Conn., No. JKB-22-2636, 2025 WL 2402194 (D. Md. Aug. 19, 2025)

Previous decision resolving some pretrial issues; this opinion comes after a bench trial, which resulted in a ruling for defendant Grace on both the patent and false advertising claims:

GWA and Grace both sell to refineries products called CO-to-CO2 combustion promoters. At a high level, GWA claims that Grace copied GWA’s patented combustion-promoter technology while embarking on an advertising campaign that falsely inflated the performance of Grace’s products and denigrated GWA in the eyes of potential buyers.

At least for people in sophisticated industries, the decision offers a roadmap for convincing a court that advertising claims are not ultimately material, no matter how factual or central they seem at first.

Domestic buyers of combustion promoters are about 110 FCC refineries in the United States, owned by about thirty companies. (Neither Grace nor GWA is the biggest competitor in the field, if you’re wondering, although it’s not a crowded market; Grace has between 20-30% of the market and GWA has made at least some sales to about half of the relevant companies. In the abstract, “if a sale does not go to Grace, it is at least as likely (indeed, probably more likely) that it would instead go to [largest player] JM rather than to GWA.”

Grace’s OCPP purported to offer the same or similar performance as CPP, but at a lower cost. It published an article entitled “CO promoter technology development” in Petroleum Technology Quarterly, a trade magazine for the petroleum refining industry. This stated:

A customer performed a trial comparing Grace’s Optimized CPP technology versus a competitor’s lower palladium promoter. … On average, the usage rate for Optimized CPP decreased by 64%.... Even though there was a lower usage rate of Optimized CPP, the afterburn was reduced by 11% [compared to the competitor].

The article also claimed the “additional benefit of lower NOx emissions,” and that OCPP particles have a higher proportion of noble metals “residing on the outer surface of the particle.” The PTQ Article was based on a case study of a trial conducted at Valero-Wilmington, which compared the performance of GWA’s GFP with Grace’s CPP and OCPP. The author stated in an internal Grace email that he wanted to “work” the analysis “into a marketing package, to support the roll out of Optimized CPP, and to protect/capture business vs GWA.”

Did claims in emails to potential clients constitute “commercial advertising or promotion”? Yes, they were sufficiently disseminated given the size of the market. “Taken together, a large minority of FCC units throughout the United States received the promotional materials.” Grace argued that the relevant market was worldwide market, but “the law is clear that an organized campaign targeting a significant subset of customers is sufficient.” The statements were prepared with the expectation of being used for a marketing campaign, and were so used.

Falsity: Grace ultimately didn’t contest that there were errors in the data and their evaluation.  The comparative-performance claims were literally false because they were not supported by the data on which Grace relied. Some industry participants read PTQ regularly and consider it to be well-known in the petroleum refining industry, while others never read PTQ or have never even heard of it. “[I]n the absence of additional evidence specific to a particular refinery, it is merely possible—not likely—that a buyer at that refinery had read any portion of the Q2 PTQ issue (much less the specific article at issue in this case) before purchasing OCPP.”

Grace also made a similar blog post, but “[t]he only witness who testified to seeing the blog post before this lawsuit began was [plaintiff’s principal] Mr. Aru himself.”

Grace also prepared “data sheets” containing much of the same information, including comparative-performance claims, NOx claims, and “outer surface” claims. These were often sent by email to refineries or shared during meetings. They also often made more detailed claims about NOx emissions (the “test-validated NOx claims”).

Although the article’s author put together a “marketing case study,” he also contemporaneously received information from the data collector that OCPP performed merely fifty-four percent better than the competition, not sixty-four percent as Grace would later claim. Meanwhile, in internal Grace communications, he repeatedly stated that OCPP’s performance as compared to GFP was the same or merely slightly better, and stated that, in a trial at another refinery, it actually performed worse. “In other words, at the very same time that Grace was trumpeting a sixty-two or sixty-four percent improvement, Grace’s internal communications show that the company knew the products basically performed the same.”

The lower NOx emissions claims, however, had weak support; because GWA had the burden of persuasion on falsity, it failed. The test-validated NOx claims could be based on a ten-year-old study, because that study “included data on at least one batch of combustion promoter that was materially identical to modern-day OCPP.” GWA didn’t offer any reason to think that the underlying science has changed. Even if Grace implied that its testing was recent and conducted on actual commercial OCPP samples (as opposed to test samples that were functionally equivalent), “misleading implications will generally not support a finding of literal falsity.”

GWA’s real troubles were materiality and, relatedly, harm. Although the comparative performance claims were likely to influence a refinery’s decision whether to trial OCPP, they were unlikely to have much influence on a refinery’s decision to purchase OCPP long term. And the test-validated NOx claims (assuming falsity) were not likely to influence the purchasing decision.

In the industry, advertising was just not very important:

Selling combustion promoters is not like selling soft drinks. A splashy advertising campaign is simply not going to move the needle very much for the target audience. The evidence at trial showed that buyers in the combustion-promoter market are hard-nosed engineers and corporate executives who are focused on their bottom line at their refineries. They are inherently skeptical of any promotional claims—and they have the means to independently verify such claims. They closely monitor, on an essentially continuous basis, performance metrics at their facilities. Furthermore, they almost universally insist on doing their own testing of any product before making a long-term purchase.

Buyers in the petroleum refining industry do not take advertisements at face value. Perhaps most strikingly, two witnesses called by GWA expressly denied ever relying on something in a PTQ publication when making a purchasing decision. …

Further, testimony indicated that some customers might have found the comparative-performance claims implausible on their face, or else too vague to be given any weight. Even if customers thought the claims were accurate in the narrow sense of representing the performance of that specific trial, they might still doubt whether the product would perform as well in their own refinery. There is a high degree of variability in FCC units, such that a product that works well in one unit might not work nearly as well in another.

Ads do “play a limited, but important, role in getting the seller’s foot in the door of a potential buyer.” Because of their continuous monitoring, a refiner will “know pretty quick” after trialing a new product “whether it’s working or not.” A trial does not guarantee a long-term sale, as multiple instances in the record confirmed.

“Several of the issues highlighted in the Grace advertisements—control of afterburn, control of CO emissions, control of NOx emissions, and cost-effectiveness—are among the most important considerations for combustion-promoter buyers.” Thus, the comparative-performance claims were, at least in the abstract, likely to influence a refinery’s decision to trial OCPP. “Although purchasers are inherently skeptical of promotional claims, they do not ignore such claims either. Instead, they consider promotional claims as part of the totality of information they would review in deciding whether to try out a new product.”

Non-advertising factors such as risk, price, and vendor relationships also affect buying decisions. Grace often charges more than competitors, in part because it offers high-quality technical support and can often troubleshoot within a twenty-four- to forty-eight-hour window, which is “among the best” in the industry and which GWA couldn’t always match. Each day that an FCC unit is offline could translate into “thousands or tens of thousands of dollars” lost. Grace is also more protected against supply disruptions than GWA, and, as a larger company, offers a full range of products, allowing it to offer package deals and a single source solution. Combustion promoters are a small percentage of refineries’ costs, on the order of five percent or less of refineries’ spending on FCC products, so they may not be central to purchase decision.

Ultimately, the comparative-performance claims were likely to influence a trial, but not a long-term purchase. And the “test-validated NOx claims” were also unlikely to influence the buying decision—not even for a trial run.

In these circumstances, it didn’t matter that the statements “relate to inherent qualities of combustion promoters” or “that Grace hoped that its advertisements would influence consumers.” “Clearly Grace must have expected some benefit from its advertisements; the Court would not lightly conclude that Grace views its own advertisements as a waste of money.” But there’s a differnece between finding that advertisements “lead to prospects” in the relevant market and finding that the advertisements were “likely to influence any purchasing decision.” Not all advertising is material as a matter of law. Still, Grace’s intentions “are highly relevant insofar as they reflect the outcomes that seasoned industry insiders expected from the advertisements.”

“[N]umerous courts have found an absence of materiality in Lanham Act false-advertising cases when the target audience consisted of sophisticated individuals who were unlikely to be swayed by promotional materials.” But in the market here, a trial was a sale, “albeit a small one,” and the statements here were material to a decision to run a trial—the only way for a refinery to evaluate claims like this. The court also noted that, “although the exact scale of the errors in the comparative-performance claims is unclear, Grace’s own communications suggest that they were overstated by at least a factor of two. This was no minor misstatement; instead, Grace’s comparative-performance claims were simply wrong, perhaps extremely wrong.” That’s relevant to materiality too.

Even though no witness admitted to being influenced by an ad, “the Court infers from the evidence that the advertisements were likely to influence purchasers’ decision to run a trial.” That’s enough for materiality, which is distinct from injury. [It wasn’t always, historically.]

And GWA was unable to show injury on a refinery by refinery basis. No witness testified that the challenged claims had any actual influence on their decisions or caused them to think less of GWA or GWA’s products (though they agreed that this was hypothetically possible), and GWA was able to identify only a single lost sale (but it didn’t seek disgorgement for that refinery, and the reason for the lost business wasn’t based on Grace’s ads but on errors on GWA’s end). 

GWA argued that, because it sought disgorgement, it need not prove “actual damages, only a likelihood of injury.” But likely injury is an element of the underlying liability determination (as it isn’t for trademark infringement). “[W]henever a plaintiff seeks to invoke the Lanham Act to remedy a past violation, it must show that the violation proximately caused an actual injury.” The requirement that a plaintiff seeking monetary relief for past harm have suffered an actual injury

“is not a minor or technical element of a Lanham Act claim; indeed, as the Supreme Court has explained, it is the core requirement that a plaintiff ‘show economic or reputational injury flowing directly from the deception wrought by the defendant’s advertising’ that assures Article III standing in Lanham Act cases.” Stemming as it does from foundational jurisdictional principles, this requirement is not lessened when the financial remedy sought is equitable (e.g., disgorgement of ill-gotten profits) rather than legal (e.g., damages) in nature.

[Now do trademark!] A Lanham Act plaintiff seeking equitable monetary relief need not prove the specific dollar amount of harm it suffered, but still must satisfy the actual injury requirement. But what about cases that say things like “[t]he Lanham Act permits recovery of profits because actual damages are often difficult to prove. It ‘shifts the burden of proving economic injury off the innocent party, and places the hardship of disproving economic gain onto the infringer.’ ” Hard Candy, LLC v. Anastasia Beverly Hills, Inc., 921 F.3d 1343, 1353 (11th Cir. 2019)? They must “be read in harmony with Lexmark’s admonition that a Lanham Act plaintiff seeking monetary relief must plead and prove actual injury proximately caused by the defendant’s conduct.” Such cases mean only “that a plaintiff (1) need not prove the specific dollar amount of losses it suffered and (2) need not prove economic harm at all, because non-economic harms, such as a loss of goodwill, are sufficient.” [How are those shown in trademark cases, again?]

The statute’s burden-shifting on disgorgement “means at most that, if, but only if, a disgorgement-seeking plaintiff has persuaded the factfinder that it suffered some injury proximately caused by the defendant’s false advertising, then the burden shifts to the defendant to prove that certain sales were not attributable to that false advertising.… In other words, a plaintiff can unlock the doors to the Lanham Act’s favorable burden shift only after it has first proved that it suffered an injury proximately caused by the defendant’s violation.”

That was fatal. Even if Grace’s advertisements were “one factor among many that may have contributed, in some attenuated sense, to GWA’s not having made sales to the refineries at issue, … that alone is not enough to satisfy the proximate-cause requirement.” The injury (if any) “might instead have resulted from ‘any number of other reasons.’ ” Nor did GWA show any harm to its goodwill.


class certification partly granted in Tesla self-driving case

In Re Tesla Advanced Driver Assistance Systems Litig., No. 22-cv-05240-RFL, 2025 WL 2391446 (N.D. Cal. Aug. 18, 2025)

While not adopting all plaintiffs’ arguments, the court certifies a limited class to challenge Tesla’s full self-driving claims. I’m going to omit a lot, but the claims are the usual California statutory claims plus fraud, negligent misrepresentation, and negligence.

Of note, because Tesla doesn’t pay for traditional marketing/advertising, “it reaches consumers directly through its website, as reinforced by its own YouTube, Instagram, press conferences, sales events, marketing newsletters, and CEO Elon Musk’s personal Twitter account.” There’s a bizarre redaction of historical fact about the prices offered to the public: “Tesla has historically offered customers the ability to purchase or subscribe to optional technology packages—ranging from [redacted] to [redacted] in price—designed to enable autonomous vehicle operation.”

Plaintiff allegedly relied on two misrepresentations to pay an extra $8000: (1) that Tesla vehicles are equipped with the hardware necessary for full self-driving capability, and (2) that a Tesla vehicle would be able to drive itself across the country within the following year. Musk touted the hardware for “full self-driving for driver-less capability” in 2016, claiming it was “in every car we make.” These statements also appeared on Tesla’s website, including on the Autopilot, Model S, and Model X subpages, and other places.

Hardware updates followed, and “Musk later stated on a 2024 earnings call that a hardware upgrade may be necessary for customers who purchased FSD with prior hardware configurations.”

In 2016, Musk also claimed that “we will be able to demonstrate a [demonstration] drive of our full autonomy all the way from LA to New York.” He tweeted words to this effect three times. Embarrassing: “While Musk’s Twitter account has over 200 million followers, the 2019 Tweet generated around 2,000 engagements, and the 2017 Tweet generated around 300 engagements.” Also in 2016, “Tesla began displaying a video that showed a Tesla driving autonomously, which remains on the Tesla site today” and was also on YouTube.

It’s undisputed that Tesla has not yet provided cross-country capability, and Tesla has not even applied for regulatory approval to deploy a Society of Automotive Engineers  Level 3 or higher vehicle in California, which is a necessary step for approval of a full self-driving vehicle. Before this ruling, the court compelled arbitration as to one group of plaintiffs and dismissed all warranty claims but permitted fraud-based, negligence-based, and related statutory claims based on the statements above.

The court thus certified a class of California purchasers/lessees who opted out of the arbitration agreement or who paid before the arbitration agreement came in and who bought or leased while the key statements were being made.

The number of people estimated to be in the class was redacted (again, why?) but numerosity was satisfied.  Commonality and predominance were also satisfied because the case turned on whether Tesla’s statements were deceptive to a reasonable consumer. Tesla argued that there was no showing of class-wide exposure where there was neither a product label nor a traditional mass advertising campaign.

Plaintiff met his burden of showing class-wide exposure on the hardware statement, but not the cross-country statement. The hardware statement was (1) on the “Autopilot” subpage of Tesla’s website from October 2016 until August 2024; (2) on various other subpages of Tesla’s website, including the “Model X” and “Model S” pages, at points throughout that period; (3) disseminated by Musk at a high-profile conference in 2016; (4) stated in a Tesla blog post published in October 2016; (5) stated in a Tesla quarterly earnings call in May 2017; and (6) sent via newsletter to prospective and current Tesla vehicle owners in 2016. “While these channels alone may not ordinarily be enough to establish class-wide exposure for a traditional car manufacturer, Tesla’s distinctive advertising strategy warrants a departure from the typical approach.”

Given Tesla’s direct-to-consumer sales and lack of independent dealers, consumers are “highly likely to visit the website when considering the purchase of an expensive package such as EAP or FSD.” The undisputed evidence “indicates that the Autopilot page is the principal source of detailed marketing information from Tesla, and typically the only written source of such information, describing the supported features and how they work. Additionally, consumers can order those packages directly through the site.” Thus, “it is reasonable to infer that almost all consumers spending thousands of dollars on the packages would review Tesla’s description to make that decision.”

Further, “because Tesla itself serves as the primary source of product information, it is reasonable to infer that the few alternative sources available to consumers—i.e., YouTube videos demonstrating self-driving capability, word-of-mouth, news articles—reinforce Tesla’s core message that full-self driving capability is on the horizon, even if they do not specifically contain the Hardware Statement.” Plaintiff’s expert also supported this finding. However, without the hardware statement on the Tesla site, “the remaining channels of communication are insufficient to support an inference of class-wide exposure,” which led the court to limit the class period to the time the statement was on the site.

As with product labels, “though some consumers may not read the packaging when opening an item, courts have inferred class-wide exposure based on the ‘inherently high likelihood’ that consumers would have relied upon those representations when encountering them in the course of purchasing the product.” Monthly Tesla website traffic data did not show otherwise; Tesla contended that only a few thousand people visited tesla.com/autopilot the related blog post:

But this information has little bearing on the key issue of the proportion of FSD purchasers who viewed those pages, as it is reasonable to assume that many people visit the Tesla website for reasons other than to purchase FSD. Moreover, the table does not include the number of monthly visits to the Model X and Model S subpages, which also contained the Hardware Statement at certain points throughout the relevant time period, and is missing large portions of data (i.e., from January to November 2017 for tesla.com/autopilot). Indeed, the view counts are consistent with a finding of class-wide exposure, as it appears thousands of people on average—which does not include those using ad blockers—viewed the Autopilot page and blog post each month throughout the class period. Tesla has therefore failed to rebut Plaintiff’s showing of class-wide exposure as to the Hardware Statement.

But the cross-country statement was less well-disseminated (Musk only said it four times and didn’t get much engagement when he did), so class-wide exposure was not established.

Materiality is an objective standard, and plaintiff showed it with testimony from a marketing expert who explained that these statements were material “due to the objective credibility of the speakers (i.e. Tesla itself and Musk, Tesla’s CEO and an industry leader), existence of multiple channels conveying a consistent message, centrality of statement to the product’s core qualities, and clear nature of the promise.”

Tesla argued that its disclosure on the Tesla website that FSD functionality was subject to “validation and regulatory approval,” as well as other “manuals, contracts and [ ] documents [that] made it crystal clear that the technology was for ‘driver assistance’ and NOT to replace the driver” disproved materiality. But “a consumer can simultaneously believe that his car has the hardware necessary to enable full self-driving and that such functionality would only be released to him after regulatory approval.” The “manuals, contracts and [ ] documents,” likewise referred to a Tesla vehicle’s current capabilities, not the full self-driving capability touted by Tesla and Musk as being possible using the existing hardware. Nor did the testimony of a “handful” of customers perceiving the Hardware Statement to be “mere puffery” undermine the common evidence demonstrating materiality, because the standard is objective. However, this conclusion only applied to the FSD package, not a lesser package.

Tesla also argued that falsity wasn’t subject to common proof because it kept tweaking the hardware. But Plaintiff’s expert reviewed the sensor and compute configurations for Tesla vehicles throughout the class period and testified that, for example, “[t]he [in]ability for the sensors to perform in bad weather” is a limitation that would be common across the different hardware versions. “Moreover, that Tesla has been unable to demonstrate a long-distance autonomous drive with any of its vehicles or obtain the required certifications to do driverless testing in California further supports the lack of full self-driving capability across the class.”

Damages were also subject to common proof because plaintiff’s theory was that the appropriate measure of damages would simply require refunding class members the amounts paid for their purchases or subscriptions to FSD.

Nor would statute of limitations issues preclude class treatment; individual application of a limitation period to a class member rarely does. Also, the delayed discovery rule and equitable estoppel theories of tolling “turn primarily on the objective inquiry of whether Tesla’s misrepresentations to the class stopped a consumer from discovering the cause of action or pursuing a lawsuit.”

The court also certified an injunctive class of members of the classes above “who have stated that they would like to purchase or subscribe to FSD in the future but cannot rely on the product’s future advertising or labelling.” Tesla argued that this was subjective, but ascertainability is not a requirement for certifying a Rule 23(b)(2) class.  And the requested injunctive relief was clear enough: “Plaintiff seeks to stop Tesla from continuing to state that its vehicles have the hardware capable of full self-driving until the vehicles are actually able to do so.


Recommended reading: Jessica Litman, Authorship Nonsense

 Read it here.

Abstract:

Copyright law's primary device for promoting progress is to bestow rights on the authors of works. Rights vest automatically and last for a very long time. Authors' choices to retain, license, or transfer those rights fuel opportunities to communicate the works to their audiences. The copyright system's mechanisms for determining who authored works (and therefore automatically obtained copyright rights) should be both accurate and reliable, since misidentifications will undermine the law's working as intended. 

This article examines authors' creation of works and copyright law's handling of authorship disputes. Many works result from creative collaboration. Although the copyright statute incorporates mechanisms for allocating rights among multiple contributors, judges appear to be uncomfortable with severally-authored works. Accordingly, courts have adopted rules that minimize, reallocate, or erase the creative contributions of inconvenient collaborators. These well-settled rules are nonsense, neither well-reasoned nor probative. They complicate and confuse our efforts to identify the author and owner of copyright in a work, and exacerbate power disparities in unbalanced creative ecosystems. 

Tuesday, August 19, 2025

court rejects Schedule A claims against sellers of compatible parts/accessories

Bestway Inflatables & Material Corp. v. Individuals, Corporations, Limited Liability Companies, Partnerships, & Unincorporated Associations Identified on Schedule A Hereto, 2025 WL 2380699, No. 24 C 11697 (N.D. Ill. Aug. 15, 2025)

When they tell you that Schedule A cases are against counterfeiters, keep in mind that trademark owners are willing to call pretty much anything “counterfeiting,” including ads for compatible parts. Here, the court looks into the allegations—assisted by defendants who showed up—and concludes that they’re implausible as to the fighting defendants (those who weren’t dismissed due to settlement—which this result suggests may have been unnecessary). What about the rest? The court allows them to show up on their own and repeat the prevailing defendants’ arguments—which probably won’t do much to curtail the practice absent some big fee shifts.

Defendants sell parts and accessories for above-ground pools via internet storefronts on third-party platforms, including Amazon.com, where their listings mention Bestway as a maker of equipment with which their products are compatible. Each of defendants’ listings “states in some way that their products are compatible with Bestway pools or meant for use in Bestway pools,” e.g., one listing states that its cup holders are “[p]erfect for above ground pools of brands such as Bestway, Intex, Funsicle, Summer Waves ... Coleman, etc.,” while another defendant’s listings state that its pool plunger valve is “for Intex/Bestway/Coleman Pool[s]” and its pool pipe holder is “for Intex Bestway Coleman Above Ground Pool,” and another says that its pool hose adapter is “for Bestway for Coleman for Intex” and its joint hose connector is “for Intex Bestway Coleman.”  

As a general matter, “it is not trademark infringement for a manufacturer of parts to truthfully inform buyers that its parts will fit the trademarked product of another manufacturer.” However, “the exact language of the advertisement will be carefully scrutinized” to ensure that it is not “confusing as to source, sponsorship, affiliation or approval.” Here, the listings “plainly used the mark ‘Bestway’ not for any source-identification function as to their own products, but only to indicate that their parts and accessories are compatible with Bestway pools.” Each listing referred not only to Bestway but also to at least one other manufacturer of above-ground pools, such as Intex or Coleman.

Defendants pointed to an earlier Schedule A case, Roku Inc. v. Individuals, Corps., LLCs, Partnerships, & Unincorporated Associations Identified on Schedule A Hereto, No. 22-CV-0850, 2022 WL 1598208, at *4 (S.D.N.Y. May 20, 2022), which concluded that the holder of the “Roku” trademark had not shown a likelihood of confusion based only on an Amazon listing of a remote that was listed as “compatible” with Roku TVs, reasoning in part that the fact that the remote had a “Roku channel” button did not communicate sponsorship or a common origin with Roku-manufactured products when there were also buttons for “Netflix, Hulu, [and] Disney+.” It was clear in context that the defendant’s use of the term “Roku” in its listing referred to “legitimate Roku products,” not to defendant’s own products. The same was true here. There were no non-conclusory allegations of actual confusion or intent to palm off. And, though “[a] superficial glance at the other likelihood of confusion factors might seem to suggest that they favor Plaintiff, … any such assessment would fail to account for context and common sense.” The mark was used “in its simple textual form,” along with the marks of competing above-ground pool manufacturers, “to inform consumers that their parts will fit the pools of those manufacturers.” If “Bestway” had been in larger font than the rest of the text or singled out in some other way, the result might have been different. [This is nominative fair use without the label, deployed as implementation of Twiqbal. If all we have to limit trademark rights is context, then it’s good for courts to take context seriously. But the Seventh Circuit has a very distinct attitude towards common sense.] Here, the mention of other competitors signalled a lack of source- or sponsorship-indicating use, suggesting that “Bestway” was being used “not to indicate sponsorship but only to identify Plaintiff’s pools as an example of one kind of pool that Plaintiff’s parts and accessories will fit.” If these listings could infringe,

it is hard to see how anyone in Defendants’ position could sell replacement parts without risking a trademark infringement suit, short of offering an explicit disclaimer—i.e., “These parts are not manufactured by Bestway, Intex, or Coleman.” Plaintiff has cited no authority requiring such language in circumstances such as these, nor does the Court see anything plausibly misleading or confusing in Defendant’s listings that might require some such corrective disclosure.

The court didn’t reach “fair use” arguments as such because confusion was implausible. Two other defendants filed motions for summary judgment on similar grounds, but the parties hadn’t yet had an opportunity for discovery; those defendants could now refile. (If the grounds were similar, what more could discovery have revealed that would change the content of the listings over which plaintiff brought suit?)


Monday, August 18, 2025

drug company plausibly alleged confusion about partnership but not falsity of "same drug" claims about Canadian imports

AbbVie Inc. v. Payer Matrix, LLC, No. 23 CV 2836, 2025 WL 2374490 (N.D. Ill. Aug. 15, 2025)

AbbVie sells the specialty drugs Humira, Skyrizi, and Rinvoq. Payer Matrix is “an alternative funding provider that works with self-funded health plans to lower their specialty drug costs.” AbbVie brought various claims against Payer Matrix based on Payer Matrix’s alleged involvement with AbbVie’s charitable programs, including AbbVie’s Patient Assistance Program (PAP) and Co-Pay Assistance Program (CAP). AbbVie also brought claims based on Payer Matrix allegedly facilitating the importation of AbbVie drugs from Canada. The court allows some claims to proceed, including trademark claims despite the sophistication of the consumers.

A RICO claim survived, amazingly enough.

Lanham Act false association: AbbVie’s complaint identified a Payer Matrix presentation “showing AbbVie’s trademark-protected logo and the trademarks of other pharmaceutical manufacturers under a title ‘We partner with top manufacturers.’ ” OK, even I would not say “partner with” is ok absent a relationship.

On the other hand, the court also thought another statement in a presentation plausibly suggested a business relationship, which seems silly to me. Discussing a slide that included AbbVie’s logo under a title “Top Manufacturers,” the presenter said pharmaceutical manufacturers were putting specialty drugs “down two runways”:

One is the traditional plan sponsor access system, by which you’re paying probably 1,000 times what it costs them to make the drug, and then there’s another pathway you can follow, which is the Manufacturer Assistance Program, and really, what these big pharma organizations are doing is they’re allowing access on both sides, but frankly, a lot of people don’t know how to get access to the side that’s significantly reduced in cost, and they do it for a variety of reasons ... but the bottom line is we’re a model that’s actually helping plans tap into these programs, which are overfunded and underutilized.

Then, back to something that is a bit more plausible, the presenter “told his audience that by permitting Payer Matrix access to its PAP and CAP programs, AbbVie was improving its reputation; earning a tax deduction; and ‘expand[ing] the net of who they’re getting onto these particular drugs.’” And then back to silly: AbbVie also alleged that other Payer Matrix “marketing materials deceptively represent[ed] that its program leverages ‘extensive, often unused funds made available by Pharma Manufacturers.’ ”

As a whole, “these statements could plausibly confuse a plan sponsor into believing that AbbVie approved of Payer Matrix’s PAP and CAP activities.” The court emphasized the bad “[w]e partner with top manufacturers” slide, as well as an allegation that at least one plan sponsor working with Payer Matrix “was led to believe and represented to its members that Payer Matrix seeks ‘grant money’ from pharmaceutical companies to reduce the cost of some specialty drugs.” But the court also highlighted the statement that AbbVie “win[s] from a financial standpoint” by accepting patients into its “overfunded and underutilized” PAP, reasoning that “a plan sponsor could rationally understand such a statement to mean that AbbVie endorses Payer Matrix’s scheme of enrolling members in the PAP.” This seems clearly fixable with a proximate disclaimer (and eliminating the partnership language).

“Partner” was also not puffery, since it has a defined meaning, i.e., “to join with another person or organization in a business activity.” Nor was client sophistication enough to defeat the argument at the pleading stage.

As to drug importation, AbbVie alleged that the medicines Payer Matrix imports, or helps import, from Canada are “likely to cause consumer confusion, given the material differences between these medicines and their domestic counterparts.” AbbVie argued that it only needed to show a material difference in the products, but § 1125(a)(1)(A) still requires a false or misleading representation “likely to confuse or deceive their audience about the plaintiff’s ‘affiliation, connection, or association’ with the defendant ‘or as to the origin, sponsorship, or approval of his or her goods, services, or commercial activities.’ ”

And “the closest AbbVie comes to meeting this mark is its allegation that Payer Matrix advertises RxFree4Me’s Canadian-sourced medicines as the ‘same brand medications.’” That “says nothing about whether AbbVie sponsors or approves of the drugs’ importation and the processes and procedures through which the importation happens.” Thus, it wasn’t plausible that AbbVie would be held “responsible for any medicine shipping delays and any counterfeit, adulterated, mislabeled, ineffective, or spoiled product that [patients] receives through Payer Matrix’s program.” And, while “same brand” “inherently suggests some affiliation or association between AbbVie and the imported AbbVie-branded drugs, AbbVie also alleges nothing to suggest that this intimation was, in fact, false or deceptive.” This is a really useful point about grey market goods—if they’re imported not for resale by someone who understands they’re importing, then there’s really nothing misleading even if there are material differences.

False advertising: AbbVie challenged: (1) advertisements on Payer Matrix’s website saying that patients will not experience any disruption or change in their specialty drug access, (2) statements Payer Matrix made to doctors during drug-conversion efforts, (3) statements made to plan sponsors, brokers, and doctors about AbbVie’s restrictions on PAP access, (4) Payer Matrix’s representations that the imported AbbVie medicines come from “legitimate and valid” sources, and (5) Payer Matrix’s statements about partnering with AbbVie.

Ads claiming no disruption or change in access: Payer Matrix’s website read: “[M]embers are not disrupted and always receive their medications. There is no interruption in supply, no requirements to change brands or dosing, the only difference is the source of the medication, and of course the reduced costs.” AbbVie alleged falsity because (1) “members do in fact have interruption in supply, including medicine delays,” (2) “Payer Matrix does ask the members’ [health care providers (“HCPs”)] to change their medicine brands when Payer Matrix is unable to maneuver the members into AbbVie’s PAP,” and (3) “the statement that ‘the only difference is the source of the medication’ misleadingly suggests that Payer Matrix is the members’ new insurance provider for their specialty drugs.”

Payer Matrix argued that AbbVie’s injury was not proximately caused by these statements.  But “AbbVie’s theory of economic harm is plausible: when the advertisement turns out to be false, customers may very well wrongly blame AbbVie—not Payer Matrix—for interruptions in supply or changes to their medications…. At this early stage, AbbVie plausibly pleads under Lexmark that its reputation was harmed by the allegedly false representations on Payer Matrix’s website.”

Statements to doctors: AbbVie alleged false and misleading statements to doctors that the patients no longer had the ability to obtain their AbbVie drug and that the HCPs, therefore, had no choice but to change their prescriptions.” Allegedly, “Payer Matrix employees would typically tell the HCPs that the patients were uninsured for specialty drugs and/or no longer had access to AbbVie’s PAP, often disparaging and blaming AbbVie in the process.”

But these statements weren’t made “in commercial advertising or promotion.” Whether this violated other laws was “beside the point”: when talking to doctors, “Payer Matrix was not trying to ‘promote’ or ‘advertise’ anything” but to persuade doctors to switch prescriptions. “[I]f Payer Matrix were trying to promote its services, the ‘relevant purchasing public’ would be plan sponsors and their brokers—not doctors.”

Alleged disparagement campaign: Payer Matrix emails allegedly stated that: (1) “AbbVie has cut off PAP access to any patients working with third parties and patient advocacy groups,” (2) “AbbVie has shut the door on PAP to those who are underinsured,” (3) “AbbVie has been converting existing Humira patients to Skyrizi for financial gain,” and (4) “AbbVie is no longer accepting PAP applications at all.” Again, these weren’t commercial advertising or promotion, but rather statements made in the course of “providing services it had already agreed to provide”:

While some cases suggest that statements made to a company’s existing customer base can support a Lanham Act claim, the statements still must “advertise” or “promote” the company’s product or services. These statements plainly did not. If anything, as Payer Matrix points out, the statements would have deterred customers from working with Payer Matrix “given that AbbVie[’s] own allegations contend that the accessibility of PAP programs is a necessary prerequisite to Payer Matrix’s business model.”

Statements about imported drugs: AbbVie alleged that Payer Matrix falsely claimed “that the medicines obtained through its importation program ... come from ‘legitimate and valid sources,’ despite the fact that these medicines are being illegally imported from outside the United States.” This was ambiguous: “generic words such as ‘legitimate’ and ‘valid’ cannot reasonably be construed as synonymous with ‘FDA-approved’ or ‘FDCA-compliant.’ ” Also, Payer Matrix said that, as part of RxFree4Me’s international drug sourcing program, “[m]embers receive their same brand medications delivered to their door for a $0 copay.” AbbVie didn’t allege that the imported medicines are not actually AbbVie-brand medicines. A reasonable person would not be misled into thinking that “same brand” means “same regulatory approval process.” Motion to dismiss as to these allegations granted.

Partnership/approval statements: Again, partnership was objectively verifiable and “plainly goes to the nature of Payer Matrix’s services.” (The other statements, though, seem at least ambiguous to me.) Still, it was “plausible that a plan sponsor listening to Payer Matrix’s presentations could be misled into thinking that AbbVie endorses (and even aids) Payer Matrix’s methods for enrolling its members in AbbVie’s PAP and CAP and that this plan sponsor would be persuaded to procure Payer Matrix’s services as a result.” [What harm does this do AbbVie?]

State law claims: Illinois Consumer Fraud and Deceptive Business Practices Act (ICFA), tortious interference, and common law fraud claims all turned on whether Payer Matrix misrepresented members’ coverage status. When facilitating its members’ PAP applications, Payer Matrix submitted requests to AbbVie saying that its members were “responsible for 100% of the cost of their drugs or that their drugs have been excluded from their plans’ formularies.” To the contrary, AbbVie alleged that the member’s employer (i.e., the plan sponsor) had every intention of covering the cost of the drug if the member was ultimately denied from AbbVie’s PAP. It alleged that Payer Matrix’s “clients’ amended [Summary Plan Descriptions] ... commonly contain language informing members that their specialty drugs will continue to be covered by the plan if Payer Matrix is unable to obtain alternate funding” and that Payer Matrix’s client brochures and marketing materials say the same, “confirming that overrides are granted as a matter of course when PAP admission is denied and that the purported specialty drug exclusion is a sham.” Thus, AbbVie plausibly alleged that Payer Matrix misrepresented the truth when it communicated to AbbVie that members were responsible for 100% of the cost of their drugs.

Payer Matrix argued that AbbVie did not rely on the submissions “given that [AbbVie] conducted independent benefits investigations,” but AbbVie alleged otherwise. And Payer Matrix was plausibly responsible even if patients formally certified the forms, given allegations that Payer Matrix (1) submitted the forms knowing they falsely represented the members’ insurance status, (2) concealed the relevant terms from patients who signed the applications, and (3) provided PBMs and plan sponsors with the forms template.

ICFA: As a non-consumer, AbbVie needed a “consumer nexus,” that is, it needed to show that “the alleged conduct involves trade practices addressed to the market generally or otherwise implicates consumer protection concerns.” Non-consumers need to show that their actions were akin to a consumer’s actions. “Consumer protection concerns” are implicated where the defendant’s conduct “involves sharp practices designed to mislead consumers about a competitor” or “public health, safety or welfare issues.”

AbbVie didn’t satisfy this standard. “Even if Payer Matrix’s allegedly deceptive conduct might ultimately hurt specialty drug patients, AbbVie does not act in a role akin to a consumer when it accepts or denies patients from its PAP and CAP.” While consumers could be harmed by delays in getting their drugs, having prescriptions changed unnecessarily, and related uncertainty, the harm to AbbVie was primarily economic: “an increase in the operational costs associated with its patient assistance programs and a loss of sales.” Operational and financial issues are distinct to access-to-health-care issues, and awarding AbbVie economic damages would not “serve the interests of consumers.” Dismissed with prejudice.

Illinois Uniform Deceptive Trade Practices Act: the prohibitions on confusion and false advertising parallel the Lanham Act, above. AbbVie argued that, “for IDTPA liability, deceptive statements do not have to occur in the context of commercial advertising.” But an IDPTA claim requires “advertising,” and the Seventh Circuit has previously applied its Lanham Act standard unchanged, so the court didn’t agree.

Tortious interference: In Illinois, a plaintiff must prove: “(1) his reasonable expectation of entering into a valid business relationship; (2) the defendant’s knowledge of the plaintiff’s expectancy; (3) purposeful interference by the defendant that prevents the plaintiff’s legitimate expectancy from ripening into a valid business relationship; and (4) damages to the plaintiff resulting from such interference.”

To the extent AbbVie’s tortious interference claim relied on Payer Matrix’s facilitation of imported drugs from Canada, AbbVie’s claim failed because there were no allegations that Payer Matrix made any false or misleading statements about the imported drugs or that Payer Matrix falsely said they are FDA-approved.

However, Payer Matrix’s facilitation of PAP applications and drug-conversion efforts could plausibly be tortious interference.

Common-law fraud: AbbVie alleged that Payer Matrix fraudulently represented to AbbVie that PAP applicants lacked commercial insurance coverage for Skyrizi, Humira, and Rinvoq, even though the plans guaranteed coverage for those medicines if they were denied PAP benefits. This requires: “(1) a false statement of material fact; (2) defendant’s knowledge that the statement was false; (3) defendant’s intent that the statement induce the plaintiff to act; (4) plaintiff’s reliance upon the truth of the statement; and (5) plaintiff’s damages resulting from reliance on the statement.” This was plausibly pled.


Tuesday, August 12, 2025

court finds unique tracking of units of fluoride products immaterial even if vaguely safety-related

Method Pharmaceuticals, LLC v. H2-Pharma, LLC, 2025 WL 2298395, No. 2:20-cv-753-ECM (M.D. Ala. Aug. 8, 2025)

Method asked the court to reconsider its ruling granting summary judgment on certain false advertising claims to H2, which sells a fluoride product as a supplement; the court declined, elaborating on its consideration of materiality. (Claims of false advertising as to FDA approval are still pending.)

At issue in this opinion is serialization (serial number tracking so each unit is unique). The court previously found that serialization was not material to the purchasing decisions of participants in the fluoride pharmaceutical market. The theory here was that market participants falsely believed that H2’s products were serialized, which contributed to their purchases.

Ignoring the procedural context, H2’s evidence indicated that customers don’t purchase based on serialization but primarily consider the price and available volume. The record evidence included contracts between wholesalers and manufactures not requiring serialization. Also, the FDA did not begin enforcing serialization until 2023—three years after H2 changed its label.

It was insufficient to argue that serialization was material because it was an “inherent characteristic.” “[T]he ‘inherent quality or characteristic’ formulation adopted by [the Eleventh Circuit] does not replace the consumer-oriented nature of the materiality inquiry with a scientific one.”

Method further argued that consumers expect fluoride products to be serialized, because consumers expect a product to comply with federal law. But that reasoning would require the court to make a finding that it couldn’t without intruding on the FDA’s jurisdiction: whether H2’s fluoride products are dietary supplements (as H2 promotes them, and which need not be serialized) or prescription drugs (which must be). Plus, there wasn’t evidence that consumers falsely believed H2’s products complied with federal law in a manner that affected their purchasing decisions; specifically, there wasn’t evidence that consumers think the products are FDA-approved prescription drugs.  

There was also a dispute over Walgreens, which allegedly agreed that Method’s and H2’s products were not substitutable, which Method argued indicated that serialization was material to Walgreens. But Walgreens continued to substitute H2’s fluoride products for Method’s even after Method sent Walgreens a copy of the original complaint in this case. “If serialization was as material to Walgreens’ decision as Method claims, Walgreens likely would have ceased … substituting H2’s products for Method’s, which Walgreens did not.” (There are also contractual failure-to-supply penalties involved; Method “never asked Walgreens the question about the reasons underlying its decision to find H2’s and Method’s products different.”)

Finally, Method argued that serialization relates to safety and is therefore material. “While the Court accepts the basic premise that safety concerns may be material, the Court is not persuaded in this instance because Method again does not show that customers make purchasing decisions based on a preference for serialized or non-serialized products because of a difference in safety.”

Monday, August 11, 2025

7-11% oversupply of caffeine in energy drink wasn't plausibly material

In Re: Prime Energy Consumer Litigation, No. 24 Civ. 2657 (KPF) (S.D.N.Y. Jul. 31, 2025)

You can tell how this will go from the first sentence: “For those consumers seeking a jolt of energy in caffeinated-beverage form, does the inclusion of a smidgen more caffeine than advertised amount to a deceptive practice?” The plaintiffs alleged that Prime’s energy drinks contain 15-25 milligrams more caffeine than the 200 milligrams represented on its labels and in its advertising. The label states: “CONTAINS: 200mg OF CAFFEINE PER 12 OZ SERVING[.]” On the side is an icon of a lightning bolt with the language: “200mg CAFFEINE[.]” But, plaintiffs alleged, “based upon testing commissioned by Plaintiffs’ attorneys, the Products actually contain between 215-225 milligrams of caffeine rather than the advertised 200 milligrams.”

First, the court finds the falsity allegations insufficient, lacking information about “how many cans of the [Products] were tested, when they were manufactured, when and where they were purchased, and how the cans were selected for testing.” Merely alleging that the tests showed extra caffeine wasn’t enough. Even though plaintiffs aren’t required to disclose all the details of their testing at the pleading stage, they need some. For example, a plaintiff could rely on a press release from the New York City Department of Consumer Affairs announcing a preliminary finding that Whole Foods’ New York City locations had systematically overcharged customers for pre-packaged foods by overstating the weights of the products, but the press release explicitly stated that the “DCA tested packages of 80 different types of pre-packaged products and found all of the products had packages with mislabeled weights. Additionally, 89 percent of the packages tested did not meet the federal standard for the maximum amount that an individual package can deviate from the actual weight[.]”

“That is more information than Plaintiffs have provided here.” The court noted the absence of information “as to the number of cans tested, whether various flavors were tested, whether various lots were tested, and, importantly, how many cans tested actually contained more than 200 milligrams of caffeine.” Plaintiffs don’t have to prove the accuracy of their findings or the rigor of their methodology, but they do need “some non-conclusory factual allegations as to the alleged testing.”

Separately, even accepting the allegations, it wasn’t plausible that an oversupply of such a small percentage was materially misleading. The complaint indicated that consumers of energy drinks “are generally seeking more caffeine, not less, as evidenced by their desire to purchase the Product in the first place (in comparison to, for example, purchasing a cup of coffee or a can of Red Bull, each with about half the caffeine content).” The label “energy drink” and the lightning bolt icon indicated that consumers “want a substantial amount of caffeine. Therefore, it defies common sense to suggest that it would be material that the Products contain a mere 7-11% additional caffeine — the exact thing those consumers are seeking.”

Plaintiffs suggested that the amount of caffeine was always material, particularly where adverse reactions to overdoses could occur (e.g., with children). “However, it is inconceivable to this Court that a consumer singularly focused on purchasing a beverage with a significantly-above-average concentration of caffeine would be concerned, much less disturbed, by the inclusion of a tiny bit more caffeine in that beverage.” Children were a red herring; none of the plaintiffs was a child, nor were there allegations that children consumed the drinks and suffered side effects. Given the allegations that there is “no proven safe dose of caffeine for children” and that the cans themselves contain a warning that they are “not recommended for children,” an oversupply couldn’t be material. this action.

Also, one plaintiff alleged that he’d be willing to buy the products again if they were properly labeled, indicating that the alleged 7-11% difference in caffeine content wasn’t in fact material to him.

Finally, and perhaps of even broader import, the court noted in dicta that it didn’t think there was any injury from merely purchasing a misdescribed product. (Citing Small v. Lorillard Tobacco Co., 94 N.Y.2d 43, 56 (1999) (holding that “customers who buy a product that they would not have purchased, absent a manufacturer’s deceptive commercial practices,” have not suffered an injury under General Business Law § 349).) The court disagreed with Second Circuit cases finding that alleging that consumers either paid a price premium or would not have purchased the products if they had known the truth sufficed under NY law.

Claims under other states’ laws, along with warranty, unjust enrichment, and fraud claims also failed.

 

New article: History and Tradition in First Amendment Intellectual Property Cases: A Critique

 Preprint available here.

Abstract

There are indications that the "history and tradition" approach the Supreme Court applied to gun rights and abortion restrictions may be coming for First Amendment doctrine. In intellectual property cases, it already has, with the Court using historical analogies for the right of publicity, copyright, and trademark. Unlike in the Second Amendment context, where the Court has reasoned from things earlier regulators didn’t do to strike down gun regulations today, in “history and tradition” First Amendment law the Court has reasoned by broad analogy to allow new speech restrictions.   

One lesson is that the history and tradition approach does not meaningfully constrain Justices even in low-political-salience areas like copyright and trademark, outside highly politicized contexts. The manipulability of levels of generality in making historical analogies has been justly criticized, but the IP cases provide a particularly clear contrast in outcomes from those in the Second Amendment cases, despite putatively using the same method of looking to historical models before—and even in place of—applying a means-ends test or other non-analogic scrutiny.

Visual comparison in online contract formation

Cody v. Jill Acquisition LLC, --- F.Supp.3d ----, 2025 WL 1822907, No. 25-CV-937 TWR (KSC) (S.D. Cal. Jun. 30, 2025)

I wouldn’t usually blog a consumer class action that was just about arbitration, but I want to highlight this one because of the use of images. Not only does the court include the visuals of what the consumer saw (in the course of deciding that the arbitration agreement wasn’t clearly enough disclosed to be binding), it compares those to visuals from past cases. However, it ultimately distinguishes cases that are visually similar because of the different context--a one time purchase as a "guest" compared to signing up for an ongoing relationship. Whether or not you agree with the result, kudos to the judge to looking beyond text to what the precedents actually showed.

This is otherwise a standard “deceptive discount/misleading reference price” case. JJill argued that the plaintiff agreed to arbitrate. 

She first had to click “add to bag.” 

Then “continue checkout.” 


She was then prompted to add her shipping address and select a shipping method: 


Then a payment method:

 


Then “Proceed to Order Review” and the order review page:

 


Directly above the “Place Order” button was this statement: “By clicking ‘Place Order’ you agree to J.Jill’s Terms of Use & Privacy Policy.” “Terms of Use” was a blue, underlined hyperlink. Those terms explicitly called attention to the arbitration clause at the top of the page:

 


There was a section called “Binding Arbitration Agreement and Class Action Waiver” under the “DISPUTE RESOLUTION” heading.

It was undisputed that the plaintiff didn’t have actual notice. “[A]n enforceable contract will be found based on an inquiry notice theory only if: (1) the website provides reasonably conspicuous notice of the terms to which the consumer will be bound; and (2) the consumer takes some action, such as clicking a button or checking a box, that unambiguously manifests his or her assent to those terms.” “This test has two aspects: the visual design of the webpages and the context of the transaction.”

Conspicuous notice “is a matter of whether an advisal is ‘displayed in a font size and format such that the court can fairly assume that a reasonably prudent Internet user would have seen it.’ ” The Ninth Circuit “deemed the [below] notice insufficient”:  


“The text disclosing the existence of the terms and conditions on the[ ] websites [wa]s the antithesis of conspicuous” because it was “printed in a tiny gray font considerably smaller than the font used in the surrounding website elements, and indeed in a font so small that it [wa]s barely legible to the naked eye,” whereas “[t]he comparatively larger font used in all of the surrounding test naturally direct[ed] the user’s attention away from the barely readable critical text.” Further, the hyperlink was “simply underscore[d],” without the “[c]ustomary design elements denoting the existence of a hyperlink[,] includ[ing] the use of a contrasting font color (typically blue) and the use of all capital letters.”

More recently, the Ninth Circuit concluded that, “[c]onsidering the [following] notice in the full context of the transaction, [it] would not expect a reasonably prudent internet user to be on inquiry notice of the contract” because “[t]he advisal [wa]s not ... located directly above or below the action button and [wa]s displayed in relatively small text.”


But the Ninth Circuit approved different displays as sufficient: 


With these, “a reasonable user would have seen the notice and been able to locate the Terms via hyperlink” because the “notice [wa]s conspicuously displayed directly above or below the action button” and “the ‘Terms of Use’ hyperlink [wa]s conspicuously distinguished from the surrounding text in bright blue font, making its presence readily apparent.”

Another Ninth Circuit case “found a single screen sufficiently conspicuous”:

This one “explicit[ly]” included “clear and legible” “notice on the final order review page, directly below key information such as the purchase total, and directly below the button [the plaintiff had] tapped to complete his purchase ... on an uncluttered page[,] ... not hidden or obscured” with “the hyperlinked phrase ‘terms of use’ ... colored bright green—contrasted against the surrounding white background and adjacent black text” and “the same color as other clickable links on the page, suggesting clearly that it is a hyperlink.”

Also, the Ninth Circuit reversed a district court order that found that these images failed to provide reasonably conspicuous notice:


The relevant admonition was “[d]irectly beneath the operative Play button,” “[t]he design elements use[d] ‘a contrasting font color’ making the notice legible on the dark background,” and “the sign-in screen lack[ed] clutter and use[d] ‘[c]ustomary design elements denoting the existence of a hyperlink.’ ”

Here, the notice at issue was visually on the acceptable side. While the text of the notice might be “considerably smaller than the font used in the surrounding website elements,” it wasn’t “so small that it is barely legible to the naked eye,” or placed on a cluttered page or obscured. Nor was it in a color lighter than surrounding text of a similar size. The hyperlink was both underlined and in a blue font, like other hyperlinks on the page. “Finally and critically,” the text of the notice was directly below the “Place Order” button, not “outside of the user’s natural flow.” 

But that wasn’t enough. Courts also have to “consider ... the ‘full context of the transaction,’ ” ... such as whether the type of transaction ‘contemplates entering into a continuing, forward-looking relationship’ that would be governed by terms and conditions.” Courts are more likely to conclude that a user anticipating “some sort of continuing relationship” would expect to be bound by terms, whereas a user “who simply purchases goods or avails herself of a one-time discount offer” would be less likely to form such an expectation. Relevant considerations include: (1) whether the transaction contemplates a “continuing relationship” by creating an account requiring a “full registration process,” (2) whether the user is entering a “free trial,” (3) whether a user enters “credit card information,” and (4) whether the user has downloaded an app on their phone, representing an intent to have continued access to the app.

Here, the plaintiff opted to check out as a guest, distinguishing this case from others where the Ninth Circuit found inquiry notice. The California Court of Appeal noted that “most consumers would not expect to be bound by contractual terms” when engaging in a “trivial” transaction like “the sale of a single item, such as a pair of socks.” Because “the onus must be on website owners to put users on notice of the terms to which they wish to bind consumers,” defendant failed to meet its burden of establishing that its notice was sufficiently conspicuous to bind the plaintiff to arbitration.